High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease

Matilde Marcellini, Loreta A. Kondili, Donatella Comparcola, Enea Spada, Maria R. Sartorelli, Massimo Palumbo, Maria Rapicetta

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background. There are limited data on the use of high interferon (IFN) dosage for treatment of children and young adults with hepatitis C virus infection and in those affected by thalassemia major (TM). Objectives. To assess the response of children and young adults with chronic hepatitis C disease, including those affected by TM, to high dose natural alpha- interferon (IFN-alpha). To evaluate the effect of iron overload in response to high dose IFN-alpha in young chronic hepatitis C virus thalassemia patients. Methods. We conducted a therapeutic trial of natural IFN-alpha, using 10 million units/m 2 three times a week for 6 months in 14 chronic hepatitis C patients ages 5 to 28 years; 7 also had TM. The follow-up period lasted 12 months. Results. Ten patients (73%) showed normal or nearly normal alanine aminotransferase values at the end of follow-up (biochemical response), but only five (35%) were negative for serum hepatitis C virus-RNA (complete responders). Four of the patients (57%) with TM were sustained complete responders. No correlation was found between the initial serum concentration of ferritin and response to IFN therapy. Patients infected with genotype 1b showed a poor response although high dose of natural IFN was used. Conclusions. These results indicate that IFN-alpha can be used in children and young patients with chronic hepatitis C disease as well as in those affected by TM. Treatment with high dosage natural IFN-alpha in children and young adults with hepatitis C infection does not appear to be more effective than dosages previously used.

Original languageEnglish
Pages (from-to)1049-1053
Number of pages5
JournalPediatric Infectious Disease Journal
Volume16
Issue number11
DOIs
Publication statusPublished - Nov 1997

Fingerprint

Chronic Hepatitis C
Interferon-alpha
beta-Thalassemia
Young Adult
Hepacivirus
Interferons
Therapeutics
Iron Overload
Thalassemia
Virus Diseases
Ferritins
Hepatitis C
Serum
Alanine Transaminase
Genotype
RNA
Infection

Keywords

  • Chronic hepatitis C
  • Interferon treatment
  • Pediatric patients
  • Thalassemia major

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)

Cite this

Marcellini, M., Kondili, L. A., Comparcola, D., Spada, E., Sartorelli, M. R., Palumbo, M., & Rapicetta, M. (1997). High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease. Pediatric Infectious Disease Journal, 16(11), 1049-1053. https://doi.org/10.1097/00006454-199711000-00009

High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease. / Marcellini, Matilde; Kondili, Loreta A.; Comparcola, Donatella; Spada, Enea; Sartorelli, Maria R.; Palumbo, Massimo; Rapicetta, Maria.

In: Pediatric Infectious Disease Journal, Vol. 16, No. 11, 11.1997, p. 1049-1053.

Research output: Contribution to journalArticle

Marcellini, M, Kondili, LA, Comparcola, D, Spada, E, Sartorelli, MR, Palumbo, M & Rapicetta, M 1997, 'High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease', Pediatric Infectious Disease Journal, vol. 16, no. 11, pp. 1049-1053. https://doi.org/10.1097/00006454-199711000-00009
Marcellini, Matilde ; Kondili, Loreta A. ; Comparcola, Donatella ; Spada, Enea ; Sartorelli, Maria R. ; Palumbo, Massimo ; Rapicetta, Maria. / High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease. In: Pediatric Infectious Disease Journal. 1997 ; Vol. 16, No. 11. pp. 1049-1053.
@article{45a0127af8fb4f71af1c86cfe42414e2,
title = "High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease",
abstract = "Background. There are limited data on the use of high interferon (IFN) dosage for treatment of children and young adults with hepatitis C virus infection and in those affected by thalassemia major (TM). Objectives. To assess the response of children and young adults with chronic hepatitis C disease, including those affected by TM, to high dose natural alpha- interferon (IFN-alpha). To evaluate the effect of iron overload in response to high dose IFN-alpha in young chronic hepatitis C virus thalassemia patients. Methods. We conducted a therapeutic trial of natural IFN-alpha, using 10 million units/m 2 three times a week for 6 months in 14 chronic hepatitis C patients ages 5 to 28 years; 7 also had TM. The follow-up period lasted 12 months. Results. Ten patients (73{\%}) showed normal or nearly normal alanine aminotransferase values at the end of follow-up (biochemical response), but only five (35{\%}) were negative for serum hepatitis C virus-RNA (complete responders). Four of the patients (57{\%}) with TM were sustained complete responders. No correlation was found between the initial serum concentration of ferritin and response to IFN therapy. Patients infected with genotype 1b showed a poor response although high dose of natural IFN was used. Conclusions. These results indicate that IFN-alpha can be used in children and young patients with chronic hepatitis C disease as well as in those affected by TM. Treatment with high dosage natural IFN-alpha in children and young adults with hepatitis C infection does not appear to be more effective than dosages previously used.",
keywords = "Chronic hepatitis C, Interferon treatment, Pediatric patients, Thalassemia major",
author = "Matilde Marcellini and Kondili, {Loreta A.} and Donatella Comparcola and Enea Spada and Sartorelli, {Maria R.} and Massimo Palumbo and Maria Rapicetta",
year = "1997",
month = "11",
doi = "10.1097/00006454-199711000-00009",
language = "English",
volume = "16",
pages = "1049--1053",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease

AU - Marcellini, Matilde

AU - Kondili, Loreta A.

AU - Comparcola, Donatella

AU - Spada, Enea

AU - Sartorelli, Maria R.

AU - Palumbo, Massimo

AU - Rapicetta, Maria

PY - 1997/11

Y1 - 1997/11

N2 - Background. There are limited data on the use of high interferon (IFN) dosage for treatment of children and young adults with hepatitis C virus infection and in those affected by thalassemia major (TM). Objectives. To assess the response of children and young adults with chronic hepatitis C disease, including those affected by TM, to high dose natural alpha- interferon (IFN-alpha). To evaluate the effect of iron overload in response to high dose IFN-alpha in young chronic hepatitis C virus thalassemia patients. Methods. We conducted a therapeutic trial of natural IFN-alpha, using 10 million units/m 2 three times a week for 6 months in 14 chronic hepatitis C patients ages 5 to 28 years; 7 also had TM. The follow-up period lasted 12 months. Results. Ten patients (73%) showed normal or nearly normal alanine aminotransferase values at the end of follow-up (biochemical response), but only five (35%) were negative for serum hepatitis C virus-RNA (complete responders). Four of the patients (57%) with TM were sustained complete responders. No correlation was found between the initial serum concentration of ferritin and response to IFN therapy. Patients infected with genotype 1b showed a poor response although high dose of natural IFN was used. Conclusions. These results indicate that IFN-alpha can be used in children and young patients with chronic hepatitis C disease as well as in those affected by TM. Treatment with high dosage natural IFN-alpha in children and young adults with hepatitis C infection does not appear to be more effective than dosages previously used.

AB - Background. There are limited data on the use of high interferon (IFN) dosage for treatment of children and young adults with hepatitis C virus infection and in those affected by thalassemia major (TM). Objectives. To assess the response of children and young adults with chronic hepatitis C disease, including those affected by TM, to high dose natural alpha- interferon (IFN-alpha). To evaluate the effect of iron overload in response to high dose IFN-alpha in young chronic hepatitis C virus thalassemia patients. Methods. We conducted a therapeutic trial of natural IFN-alpha, using 10 million units/m 2 three times a week for 6 months in 14 chronic hepatitis C patients ages 5 to 28 years; 7 also had TM. The follow-up period lasted 12 months. Results. Ten patients (73%) showed normal or nearly normal alanine aminotransferase values at the end of follow-up (biochemical response), but only five (35%) were negative for serum hepatitis C virus-RNA (complete responders). Four of the patients (57%) with TM were sustained complete responders. No correlation was found between the initial serum concentration of ferritin and response to IFN therapy. Patients infected with genotype 1b showed a poor response although high dose of natural IFN was used. Conclusions. These results indicate that IFN-alpha can be used in children and young patients with chronic hepatitis C disease as well as in those affected by TM. Treatment with high dosage natural IFN-alpha in children and young adults with hepatitis C infection does not appear to be more effective than dosages previously used.

KW - Chronic hepatitis C

KW - Interferon treatment

KW - Pediatric patients

KW - Thalassemia major

UR - http://www.scopus.com/inward/record.url?scp=0030684702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030684702&partnerID=8YFLogxK

U2 - 10.1097/00006454-199711000-00009

DO - 10.1097/00006454-199711000-00009

M3 - Article

VL - 16

SP - 1049

EP - 1053

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 11

ER -